Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.38 |
| ▸ | MAP2K2 | P36507 | 8/20 | 0.38 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.36 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL929529 | 0.93 | MAP2K1 (0.47) | MAP2K1MAP2K2MAP2K5EIF2AK1CA2 | |
| SCHEMBL13747653 | 0.91 | MAP2K1 (0.43) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL13748052 | 0.83 | MAP2K1 (0.54) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL929220 | 0.70 | MAP2K1 (0.43) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL390239 | 0.66 | MAP2K1 (0.68) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL5992602 | 0.65 | MAP2K1 (0.74) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL29413386 | 0.65 | MAP2K1 (0.49) | MAP2K1MAP2K2 | |
| SCHEMBL188153 | 0.65 | MAP2K1 (0.49) | MAP2K1MAP2K2 | |
| SCHEMBL29781367 | 0.65 | MAP2K1 (0.74) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL23694186 | 0.64 | MAP2K1 (0.52) | MAP2K1MAP2K2MAP2K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015392-A1 | PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226 | ASTRAZENECA AB | 2011-01-20 | — | — | US | disclosed |
| EP-2252588-A2 | PROCESS FOR PREPARING PYRIDONE DERIVATIVES | AstraZeneca AB (SE) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009101432-A2 | PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226 | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015392-A1 | PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226 | PDXK, MAPK1, PNPO | MAP2K1 172/4885MAP2K2 110/4885MAP2K5 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.